Contineum Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $278.76M
- P/E (TTM)
- –
- Dividend yield
- –
About Contineum Therapeutics
Pharmaceutical Preparations, SIC 2834
The company is a clinical-stage biopharmaceutical organization that discovers and develops small molecule therapeutics for neuro-inflammatory and immunological diseases. Its primary proprietary product candidate is PIPE-791, a brain-penetrant inhibitor of the lysophosphatidic acid 1 receptor under clinical investigation for idiopathic pulmonary fibrosis and chronic pain conditions such as osteoarthritis and lower back pain. The business also develops PIPE-307, a muscarinic type 1 receptor antagonist, in partnership with Johnson & Johnson for major depressive disorder and relapsing-remitting multiple sclerosis. It also conducts preclinical discovery targeting other related biological pathways.
The business conducts clinical development internationally, including an ongoing global Phase 2 clinical trial for its lead product candidate with planned enrollment of approximately 324 participants across clinical study sites worldwide. The organization retains worldwide commercial and development rights to its LPA1 receptor programs and broader discovery portfolio, while collaborating globally with Johnson & Johnson on select programs. Specific details regarding its headquarters location or operational facilities are not stated in the text.
Summary of the business section of Contineum Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Contineum Therapeutics, Inc.
- Headquarters
- San Diego, CA
- Address
- 3565 General Atomics Court, Suite 200 92121
- Phone
- (858) 333-5280
- Website
- contineum-tx.com
- Employees
- 51, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, San Diego, California
Stock & identifiers
- Ticker
- CTNM
- Exchange
- Nasdaq
- IPO date
- Apr 8, 2024
- Shares outstanding
- 38M, Jul 24, 2026
- Public float
- $102.10M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1855175
- CUSIP
- 21217B100
- ISIN
- US21217B1008
- EIN
- 27-1467257
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Carmine N. Stengone | CEO and President, Director | 19,717 |
| Daniel S. Lorrain | Chief Scientific Officer | 145,337 |
| Tim Watkins | CMO & Head of Development | 8,961 |
| John Stephen Healy | General Counsel and Corp Sec | – |
| Peter T. Slover | Chief Financial Officer | – |
| Stephen L. Huhn | CMO & Sr VP, Clinical Dev. | 12,800 |
| Troy A. Ignelzi | Director | – |
| Evert B. Schimmelpennink | Director | – |
| Gines Diego Miralles | Director | – |
| Todd R. Brady | Director | – |
| Sarah Boyce | Director | – |
| Olivia C. Ware | Director | – |
| Lori Lyons-Williams | Director | – |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 51 employees, all of which were full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 8, 2024 | IPO | Initial public offering priced (424B4 prospectus) |
| Apr 2, 2024 | Listing | Registration of securities on an exchange (Form 8-A) |